NCT06405152Completed
Assessment of Macrophage Activation syndromE in STill's Disease
Assessment of Macrophage Activation syndromE in STill's Disease: Retrospective Chart Analysis of Patient HistorY, Symptom Resolution and Treatment Characteristics
Source: ClinicalTrials.gov · Last updated 5 Oct 2026
Brief summary (registry, in English)
Assessment of Macrophage activation syndrome in STill's disease: retrospective chart analysis of patient History, Symptom resolution and Treatment characteristics
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 75 (actual)
- First submitted
- 9 Apr 2024
- Start date
- 27 Sept 2023
- Primary completion date
- 26 Sept 2024
- Lead sponsor
- Swedish Orphan Biovitrum
- NCT number
- NCT06405152
What you commit to
- Study type: Observational
- Participants enrolled: 75
- From 27 Sept 2023 to the primary completion date, 26 Sept 2024
- 11 sites in 7 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A diagnosis of primary Hemophagocytic Lymphohistiocytosis (HLH) prior to the beginning of the index MAS episode.
- Confirmed malignancy prior to the beginning of the index MAS episode.
- Patient treated with any investigational product as a part of clinical trial during the index MAS episode.
Who the study is looking for
- Age \>6 months and ≤80 years at the beginning of the index MAS episode.
- Diagnosis of Still's disease (sJIA (systemic Juvenile Idiopathic Arthritis) or AOSD (Adult Onset Stills Disease) diagnosis).
- Diagnosis of MAS according to treating physician in the medical record.
- Patients who have received at least 3 consecutive days of GC after diagnosis of MAS and/or are judged by the Investigator to be refractory to GC due to clinical worsening of patient's condition .
- The onset of the index MAS episode occurred between 01 January 2012 and 30 September 2022.
Age in the registry: 6 months to 80 years · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Swedish Orphan Biovitrum Research Site Coordinator of this site? Confirm its status | Calgary | Canada | Unknown status |
| Swedish Orphan Biovitrum Research Site Coordinator of this site? Confirm its status | Heidelberg | Germany | Unknown status |
| Swedish Orphan Biovitrum Research Site Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
| Swedish Orphan Biovitrum Research Site Coordinator of this site? Confirm its status | Paris | France | Unknown status |
| Swedish Orphan Biovitrum Research Site Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
| Swedish Orphan Biovitrum Research Site Coordinator of this site? Confirm its status | Rome | Italy | Unknown status |
| Swedish Orphan Biovitrum Research Site Coordinator of this site? Confirm its status | Utrecht | Netherlands | Unknown status |
| Swedish Orphan Biovitrum Research Site Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Swedish Orphan Biovitrum Research Site Coordinator of this site? Confirm its status | Cincinnati | United States | Unknown status |
| Swedish Orphan Biovitrum Research Site Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| Swedish Orphan Biovitrum Research Site Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.